Active, not recruiting psychedelic research trials
Data as of 10 October 2026. Source: ClinicalTrials.gov records held by PsychoactiveMap, refreshed from a reviewed snapshot.
Active, not recruiting is a registry status. The study is ongoing and participants are taking part, but it is not enrolling new participants. Status is reported by the study team and can change.
Educational information, not medical advice. A registry listing is not evidence of safety, benefit or results, and it is not a recommendation. PsychoactiveMap does not recruit, screen or refer participants. Status and other details are copied from the registry and can be out of date, so check the registry record and speak to a qualified health professional before any decision. Read the full disclaimer.
At a glance
- 60 registered studies are counted on this page.
Which substances
Counts per substance hub. Ketamine is limited to studies classified as psychiatric research, and records about disease-modifying therapy that match the abbreviation DMT are removed.
| Substance hub | Studies |
|---|---|
| Psilocybin | 33 |
| MDMA | 3 |
| LSD | 6 |
| DMT | 3 |
| 5-MeO-DMT | 1 |
| Ketamine | 17 |
| Ibogaine | 2 |
By phase
| Phase | Studies | Share |
|---|---|---|
| Early Phase 1 | 4 | 7% |
| Phase 1 | 16 | 27% |
| Phase 2 | 19 | 32% |
| Phase 3 | 10 | 17% |
| Phase 4 | 3 | 5% |
| Not applicable | 1 | 2% |
| Not reported | 7 | 12% |
Countries
Country is taken from the study's linked research site. 1 of 60 records have no country on file. The top 9 countries are shown.
| Country | Studies | Share |
|---|---|---|
| United States | 43 | 72% |
| Canada | 9 | 15% |
| Switzerland | 1 | 2% |
| China | 1 | 2% |
| Denmark | 1 | 2% |
| France | 1 | 2% |
| United Kingdom | 1 | 2% |
| Netherlands | 1 | 2% |
| Sweden | 1 | 2% |
When studies started
| Start year | Studies |
|---|---|
| 2024 to 2026 | 31 |
| 2020 to 2023 | 26 |
| 2015 to 2019 | 3 |
Study design
- 53 interventional and 7 observational studies.
- Median planned or actual enrolment is 31 participants (range 10 to 572, across 60 records that report it).
Topics named in study titles
A keyword match on registered titles, so one study can appear under more than one topic and a study can be missed. It describes what titles mention, nothing more.
| Topic | Studies |
|---|---|
| Depression and mood | 21 |
| Trauma and PTSD | 7 |
| Alcohol use | 5 |
| Suicidal thoughts | 4 |
| Anxiety | 3 |
| Cancer and end of life | 3 |
| Pain and headache | 3 |
| Other substance use | 2 |
Most recently started studies
The 25 studies with the latest start dates, newest first. The order is not a ranking. Each ID links to its own ClinicalTrials.gov record.
| Registry ID | Title as registered | Status | Phase | Country | Start |
|---|---|---|---|---|---|
| NCT07584720 | Study of Midomafetamine in Healthy Adults | Active, not recruiting | Phase 1 | United States | 2026-04 |
| NCT07336238 | Group Retreat Psilocybin Therapy for the Treatment of Anxiety and Depression in Patients With Metastatic Solid Tumors or Incurable Hematologic Malignancies | Active, not recruiting | Phase 2 | United States | 2026-04 |
| NCT06386003 | Psilocybin-Assisted Cognitive Processing Therapy for Chronic PTSD | Active, not recruiting | Phase 2 | Canada | 2026-03 |
| NCT07396272 | A Clinical Trial of Add-on Oral Slow-release Ketamine Treatment in Major Depression | Active, not recruiting | Phase 2 | Sweden | 2026-03 |
| NCT07275970 | Safety and Preliminary Efficacy of Organic Whole Psilocybin-Containing Mushrooms to Treat Patients Suffering From PTSD | Active, not recruiting | Phase 1 | United States | 2025-12 |
| NCT06853912 | Psilocybin With Psychological Support (Psi-PS) for Military Veterans and First Responders With Co-occurring PTSD & Alcohol Use Disorder (AUD) | Active, not recruiting | Phase 2 | United States | 2025-06 |
| NCT07463911 | Treatment Response In ECT Patients | Active, not recruiting | Not reported | Not reported | 2025-05 |
| NCT06941844 | A Phase 3 Trial of MM120 for Major Depressive Disorder (Emerge) | Active, not recruiting | Phase 3 | United States | 2025-04 |
| NCT07189988 | Observational Pilot Study to Explore the Social and Health Impacts of a New Model of Care in Oregon: Psilocybin Services on Alcoholism | Active, not recruiting | Not reported | United States | 2025-03 |
| NCT06225232 | Psilocybin in the Treatment of Cannabis Use Disorder: A-Proof-of-Concept Study | Active, not recruiting | Phase 2 | Canada | 2025-03 |
| NCT06809595 | A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Panorama) | Active, not recruiting | Phase 3 | United States | 2025-01 |
| NCT06698848 | Integrating Ketamine Effects on Neuronal Molecular Signatures and the Brain Functional and Structural Connectome | Active, not recruiting | Phase 1 | United States | 2025-01 |
| NCT06564818 | "A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder" | Active, not recruiting | Phase 3 | United States | 2024-12 |
| NCT06741228 | A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Voyage) | Active, not recruiting | Phase 3 | United States | 2024-12 |
| NCT07199179 | Link Between Reduction of Suicide Ideation by Esketamine in Add-On and Initial Levels of Psychological Pain and Anhedonia | Active, not recruiting | Not reported | France | 2024-11 |
| NCT06069843 | Single-dose Ketamine Treatment to Improve Depression in Mild Cognitive Impairment | Active, not recruiting | Phase 2 | United States | 2024-11 |
| NCT06731621 | Psilocybin for Treatment-Resistant Depression in Autism | Active, not recruiting | Phase 1 | Canada | 2024-11 |
| NCT06117306 | MDMA-assisted Massed Prolonged Exposure for PTSD | Active, not recruiting | Phase 3 | United States | 2024-10 |
| NCT06506019 | Neurobiological Effects of Psilocybin in Treatment Resistant Bipolar Depression | Active, not recruiting | Phase 1 | Canada | 2024-10 |
| NCT06496750 | Ketamine for Methamphetamine Use Disorder | Active, not recruiting | Phase 2 | United States | 2024-09 |
| NCT06565494 | MDMA-Assisted Therapy for Pathological Narcissism | Active, not recruiting | Early Phase 1 | United States | 2024-08 |
| NCT06407635 | A Study of Psilocybin for PTSD | Active, not recruiting | Phase 1 | United States | 2024-06 |
| NCT06416085 | Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) Therapy for Patients With Advanced Cancer | Active, not recruiting | Phase 2 | Canada | 2024-06 |
| NCT06303739 | Psilocybin-Assisted Therapy in Treatment-Resistant Depression | Active, not recruiting | Phase 3 | United States | 2024-04 |
| NCT06308653 | Psilocybin for Major Depressive Disorder (MDD) | Active, not recruiting | Phase 3 | United States | 2024-03 |
Other substance hubs
Psilocybin | MDMA | LSD | DMT | 5-MeO-DMT | Ayahuasca | Ketamine | Ibogaine
Registry status hubs
Recruiting | Not yet recruiting | Enrolling by invitation | Completed | Terminated | Suspended | Withdrawn
Phase hubs
Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Phase not applicable